![]() HC Wainwright reissued a “buy” rating and issued a $70.00 target price on shares of Blueprint Medicines in a research report on Tuesday, February 28th. SVB Leerink dropped their target price on shares of Blueprint Medicines from $45.00 to $38.00 and set a “market perform” rating on the stock in a research report on Friday, February 24th. They issued a “sell” rating on the stock. initiated coverage on shares of Blueprint Medicines in a research report on Thursday, March 16th. SVB Securities lowered their price objective on shares of Blueprint Medicines from $45.00 to $38.00 in a research note on Friday, February 24th. Several equities analysts have recently issued reports on the stock. 3.42% of the stock is currently owned by insiders. Insiders sold 27,696 shares of company stock worth $1,265,091 over the last ninety days. The disclosure for this sale can be found here. Following the completion of the sale, the chief operating officer now owns 55,376 shares of the company’s stock, valued at $2,529,021.92. ![]() The stock was sold at an average price of $45.67, for a total transaction of $139,704.53. Also, COO Christina Rossi sold 3,059 shares of the business’s stock in a transaction on Monday, March 6th. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Following the completion of the sale, the chief executive officer now directly owns 125,641 shares in the company, valued at $5,740,537.29. The shares were sold at an average price of $45.69, for a total value of $303,381.60. In other news, CEO Kate Haviland sold 6,640 shares of the business’s stock in a transaction on Monday, March 6th. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Blueprint Medicines news, CEO Kate Haviland sold 6,640 shares of Blueprint Medicines stock in a transaction that occurred on Monday, March 6th. Insider Buying and Selling at Blueprint Medicines will post -10.08 EPS for the current fiscal year. Research analysts expect that Blueprint Medicines Co. During the same period in the previous year, the company earned ($0.99) earnings per share. The company’s revenue was down 63.8% compared to the same quarter last year. Blueprint Medicines had a negative net margin of 273.24% and a negative return on equity of 80.09%. The firm had revenue of $38.78 million during the quarter, compared to analysts’ expectations of $33.52 million. The biotechnology company reported ($2.65) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.73) by $0.08. ![]() ![]() Get Blueprint Medicines alerts:īlueprint Medicines ( NASDAQ:BPMC – Get Rating) last posted its earnings results on Thursday, February 16th. Allspring Global Investments Holdings LLC now owns 2,719 shares of the biotechnology company’s stock worth $179,000 after purchasing an additional 434 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its stake in shares of Blueprint Medicines by 19.0% in the 3rd quarter. Neo Ivy Capital Management bought a new stake in shares of Blueprint Medicines during the 3rd quarter worth about $166,000. Affinity Asset Advisors LLC bought a new stake in shares of Blueprint Medicines during the 1st quarter worth about $127,000. Quantbot Technologies LP bought a new stake in shares of Blueprint Medicines during the 1st quarter worth about $95,000. Van ECK Associates Corp bought a new stake in shares of Blueprint Medicines during the 3rd quarter worth about $43,000. Other hedge funds have also recently bought and sold shares of the company. ProShare Advisors LLC’s holdings in Blueprint Medicines were worth $593,000 at the end of the most recent quarter. The fund owned 13,544 shares of the biotechnology company’s stock after purchasing an additional 990 shares during the quarter. ( NASDAQ:BPMC – Get Rating) by 7.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. ProShare Advisors LLC boosted its position in Blueprint Medicines Co.
0 Comments
Leave a Reply. |